ClinicalTrials.gg
CompletedNCT02280590Updated Jul 7, 2015

Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia

A Phase 4 interventional study of Rosuvastatin(Cresnon®) and Rosuvastatin(Crestor®) in Hyperlipidemia, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-07-07.

Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing rosuvastatin in Hyperlipidemias — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Hyperlipidemias.

Enrollment
11th of 30
223 · median 114
Started
2014
with 3 others
Phase 4
10 of 30
none open now
Registered
16th of 30
by date

Among the 30 studies testing rosuvastatin in Hyperlipidemias, this one is the 11th largest by enrollment, is one of 4 that started in 2014, is one of 10 in phase 4, and was the 16th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

1 of the 30 studies testing rosuvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing rosuvastatin in Hyperlipidemias, or all of them as a file.
02

Study summary

Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia

  • 8-week, active-controlled, open-label, randomized, parallelgroup, fixed-dose, noninferiority, multicenter, phase 4 design
03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥ 20
  • Persons who have not reached LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Cresnon®

    Rosuvastatin 10mg, tablet, q.d.

    Drug: Rosuvastatin(Cresnon®)

  • Active comparator
    Crestor®

    Rosuvastatin 10mg, tablet, q.d.

    Drug: Rosuvastatin(Crestor®)

06

What researchers measure

Primary outcomes

  1. The percent change in LDL-C

    Time frame: After taken medication for 8 weeks

Secondary outcomes

  1. The percent change in total cholesterol, Triglyceride, HDL-C, non-HDL-C, and non-HDL-C/HDL-C

    Time frame: After taken medication for 8 weeks

  2. The proportion of subjects reaching LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis

    Time frame: After taken medication for 8 weeks

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014 and a primary completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2014
First posted
Oct 31, 2014
Start
Sep 2014
Primary completionActual
Jun 2015
Last update
Jul 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02280590
Responsible party
Sponsor
First posted
Oct 31, 2014
Start date
Sep 2014
Primary completion
Jun 2015
Last update
Jul 7, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion